ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $6.77M |
| Net Income (Most Recent Fiscal Year) | $-53.36M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.19 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -665.83% |
| Net Margin (Trailing 12 Months) | -217.64% |
| Return on Equity (Trailing 12 Months) | -184.38% |
| Return on Assets (Trailing 12 Months) | -64.59% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.98 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.30 |
| Inventory Turnover (Trailing 12 Months) | 2.14 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.42 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 41.54M |
| Free Float | 32.94M |
| Market Capitalization | $15.16M |
| Average Volume (Last 20 Days) | 1.94M |
| Beta (Past 60 Months) | -0.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.45% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |